L-Carnitine

Overview

L-Carnitine (levocarnitine) is a small quaternary-ammonium amino-acid derivative the body makes from lysine and methionine, with red meat the richest dietary source. Its central job is to ferry long-chain fatty acids into mitochondria to be burned for energy. Only the L-enantiomer is active, which is why the drug is specifically levocarnitine. It exists in two contexts: as FDA-approved medicine (Carnitor) for primary and secondary carnitine deficiency, where it is genuinely disease-modifying; and as a popular "fat-burner" supplement, where the evidence is far weaker than the marketing implies.

Mechanism

L-carnitine is the rate-limiting cofactor of the carnitine shuttle: CPT1 converts long-chain acyl-CoA to acylcarnitine, the translocase moves it across the inner mitochondrial membrane, and CPT2 regenerates acyl-CoA inside the matrix for beta-oxidation. It also buffers the mitochondrial acyl-CoA/CoA ratio, which is why it helps in organic acidemias and valproate toxicity. Cellular uptake depends on the OCTN2 transporter (SLC22A5) — loss-of-function mutations cause primary carnitine deficiency. Separately, gut bacteria convert some dietary carnitine to TMA and then hepatic TMAO, the basis of the cardiovascular concern below.

Clinical evidence

The strongest evidence is for deficiency: in primary/secondary carnitine deficiency, levocarnitine reverses the metabolic crisis pattern (cardiomyopathy, myopathy, hypoketotic hypoglycemia). For weight loss, a meta-analysis of 9 RCTs (Pooyandjoo 2016) found a modest ~1.3 kg greater loss that shrank with longer use — far short of "fat-burner" claims. Athletic-performance evidence is mixed. The pivotal counterweight is Koeth et al. (Nature Medicine 2013): chronic dietary carnitine raised TMAO and accelerated atherosclerosis in mice, and high carnitine predicted cardiac events in patients only when TMAO was also high — an association, not proof, but a genuine flag.

Safety profile

For approved uses, levocarnitine is well tolerated; the most common effects are dose-related GI symptoms and a fishy body odor (from trimethylamine), both of which ease with dose reduction. Seizures have been reported in susceptible patients, and it can raise the INR with warfarin. The main long-term concern is the gut-microbiota TMAO pathway and its atherosclerosis association, most relevant to chronic high-dose supplementation. It is not WADA-prohibited, though a high-volume IV infusion is itself a banned method. FDA-approved for deficiency; this is reference information, not a dosing recommendation.

Compare

• vs B12

  Both are deficiency-correcting agents marketed as energy/metabolism aids; B12 has a cleaner safety profile, while L-carnitine carries the TMAO concern.

• vs LIPO-C

  Lipo-C is a compounded MIC injection that often adds L-carnitine; the standalone amino acid is far better characterized than the blend.